AI Analysis
AI-generated analysis. Always verify with the original filing.
FY2025 delivered sharply wider operating and net losses of -$25.5M and -$25.0M respectively, driven by a significant IPR&D impairment from sustained market capitalization decline, amid ongoing clinical development and acute month-to-month liquidity constraints.
Key Takeaways
1Operating income was -$25.5M (-179.0%) as losses widened due to determination that fair value fell below carrying amount from market cap decline.
2Net income was -$25.0M (-165.1%) reflecting increased expenses in clinical development programs.
3Diluted EPS was -$4.18 (50.7% improvement) despite larger overall loss, due to changes in share count dynamics.
4Net cash used in operating activities was -$5.1M, improved from prior year as clinical programs progressed with inherently higher development costs.
5Expect continued operating losses and rising R&D expenses as product candidates advance in preclinical and clinical stages.